uniQure N.V. Investors Urged to Connect with Legal Representation Following Securities Fraud Allegations

uniQure Investors Encouraged to Take Legal Action for Securities Fraud

Investors who purchased ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, are alerted by Kessler Topaz Meltzer & Check, LLP regarding a recent securities fraud class action lawsuit. This legal action, filed on behalf of affected investors, centers around significant allegations of misleading information related to the company's Huntington’s disease gene therapy drug.

Background of the Allegations

uniQure N.V. is a biotechnology firm that focuses on developing gene therapies for rare diseases, notably Huntington's disease (HD). Their primary product candidate, AMT-130, is designed to slow the progression of this devastating condition. However, it appears that throughout the class period, the company may have provided investors with materially false and misleading information about AMT-130’s clinical trials.

Specifically, it has been alleged that uniQure misrepresented the status and progress of its Phase I/II clinical trials. Furthermore, important facts about the Biologics License Application (BLA) submission timeline to the FDA were not fully disclosed, leading to a misrepresentation of the drug's viability and the company's business prospects.

On November 3, 2025, the situation took a dramatic turn when uniQure disclosed that the FDA had expressed concerns over the adequacy of the data submitted from these pivotal studies. This clarification prompted an immediate drop in share prices, evidencing the tangible impact of the alleged misinformation on investors. The price of uniQure shares plummeted by more than 49% in a single day, reflecting widespread concern among stakeholders.

Legal Options for Affected Investors

As it stands, investors who acquired uniQure shares during the stated class period have until April 13, 2026, to file a motion to serve as lead plaintiff in the lawsuit. Those interested in participating in this legal representation are advised to connect with the Kessler Topaz Meltzer & Check, LLP—where counsel is ready to provide a free evaluation of potential case options. This step is crucial for investors looking to assert their rights and seek possible recovery of their losses.

How to Act

1. Contact Kessler Topaz Meltzer & Check, LLP: Investors are encouraged to reach out without delay as the time-sensitive nature of this legal action necessitates prompt engagement.
2. Evaluate Leadership: Potential lead plaintiffs should consider their financial stakes as well as their commitment to representing the class in ongoing legal matters.
3. Consider Counsel Options: While Kessler Topaz offers guidance and representation, investors may choose their counsel or opt out if they prefer.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is a highly regarded law firm specializing in securities-class actions and protecting investor interests. With a history of securing large recoveries for clients, the firm has built a reputation recognized nationally. Their commitment to investor rights is unparalleled, and they are available to assist investors seeking guidance through this complex process.

For those affected by the allegations against uniQure, this is an opportune moment to address potential grievances and reclaim lost investments. Given the severity of the claims and the potential ramifications, reaching out to experienced legal counsel promptly could be instrumental in navigating this intricate situation effectively.

Investors interested in learning more about their options are encouraged to engage with Kessler Topaz Meltzer & Check, LLP, as they continue to advocate for shareholder rights across the board.